carbamic acid, <1-(aminomethyl)-2-methylbutyl>-, 1,1-dimethylethyl ester, | 115654-48-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: carbamic acid, <1-(aminomethyl)-2-methylbutyl>-, 1,1-dimethylethyl ester,
• 英文别名: tert-butyl ((2S,3S)-1-amino-3-methylpentan-2-yl)carbamate；(1-aminomethyl-2-methylbutyl)carbamic acid tert-butyl ester；tert-butyl N-[(2S,3S)-1-amino-3-methylpentan-2-yl]carbamate
• CAS: 115654-48-3
• 化学式: C₁₁H₂₄N₂O₂
• 分子量: 216.324
• InChiKey: KQLHRHMWZJRXEG-DTWKUNHWSA-N

物化性质

• 沸点：
  309.3±25.0 °C(Predicted)
• 密度：
  0.953±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  15
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.91
• 拓扑面积：
  64.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  carbamic acid, <1-(aminomethyl)-2-methylbutyl>-, 1,1-dimethylethyl ester, 在 氰基磷酸二乙酯 、 N,N-二异丙基乙胺 、 三氟乙酸 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 37.0h， 生成 1,3-dioxolane-4-acetamide, 5-<2-cyclohexyl-1-<<(1,1-dimethylethoxy)carbonyl>amino>ethyl>-2,2-dimethyl-α-(1-methylethyl)-N-<5-(hexahydro-2-oxo-1H-thieno<3,4-d>imidazol-4-yl)-1-oxopentyl>-, <3aS-<3aα,4β(1R*,2R*,3S*,4S*),6aα>>-
  参考文献：
  名称：

  Evaluation of a vitamin-cloaking strategy for oligopeptide therapeutics: biotinylated HIV-1 protease inhibitors

  摘要：

  The outstanding limitations to the oligopeptide as a therapeutic agent are poor oral availability and rapid biliary clearance. To address these concerns a series of eight peptidic HIV-1 protease inhibitors containing the structural segment of the vitamin biotin have been prepared. These have been evaluated with regard to the hypothesis that this vitamin would cloak the peptidic character of these oligopeptides, and thus impart to these inhibitors the potential for absorption and distribution via biotin transporters and receptors. By iterative optimization about a -Chal psi[CH- (OH)CH(OH)]Val- core inhibitory insert, three particularly potent inhibitors (K-i less than or equal to 10 nM) of the HIV-1 protease were obtained. Although excellent cell culture antiviral activity is observed for other peptidic protease inhibitors of comparable affinity, none in this series exhibited satisfactory antiviral activity. This failure is-attributed to the incompatibility of the hydrophilic and hydrogen-bonding biotin segment, with the facile membrane permeability and intracellular access presumably required for antiviral activity. The ability of the biotin to cloak the peptide, and thus render the overall appearance of the conjugate as that of a vitamin, was evaluated. Four of this series were evaluated for recognition by the Caco-2 cell intestinal biotin transporter, None inhibited competitively biotin uptake, indicating a lack of recognition. A vitamin may bind to a specific protein carrier, and thus attain an improved serum profile (by resistance to biliary clearance) and advantageous delivery to cells. Therefore, the serum concentrations of three were evaluated following an iv bolus in a rat model for serum clearance. One of the three protease inhibitors (L-idonamide, 6-cyclohexyl-2,5,6-trideoxy-2-(1-methylethyl)-5-[[3-methyl-1-oxo-2-[[5-(hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl)-1-oxopentyl]amino]butyl]amino]-N-[2-methyl-1-[[(2-pyridinylmethyl)amino] carbonyl]butyl]-, [3aS-[3a alpha,4 beta(1R*,2R*;3R*),6a alpha]]-) sustained a more than 5-fold increase in serum concentration at all time points relative to the benchmark structure. The remaining two had serum concentrations at least equal to the benchmark, suggestive of improved resistance to clearance. One(L-idonamide, 6-cyclohexyl-2,5,6-trideoxy-5-[[2-[[5-(hexahydro-2-oxo-1H-thieno-[3,4-d]imidazol-4-yl)pentyl]thio]benzoyl]amino]-2-(1-methylethyl)-N-[2-methyl-1-[[(2-pyridinyl- methyl)amino]carbonyl]butyl]-, [3aS-[3a alpha,4 beta(1R*,2R*),6a alpha]]-) was prepared as a complex with the biotin-binding protein avidin. Avidin may resemble an endogenous serum biotin carrier protein. The antiviral activity (evaluated in an H9-HTLV(IIIB) acute HIV-1 infection assay) of the inhibitor and the avidin complex was identical. This suggests that the avidin-inhibitor complex is capable of cell internalization. Although the weak antiviral activity of these biotinylated inhibitors precludes consideration as practical HIV therapeutics, the overall data remain suggestive of vitamin cloaking of oligopeptides as a strategy of potential value.

  DOI：

  10.1021/jm00028a013
• 作为产物：
  描述：

  在 肼 作用下， 以 乙醇 为溶剂， 生成 carbamic acid, <1-(aminomethyl)-2-methylbutyl>-, 1,1-dimethylethyl ester,
  参考文献：
  名称：

  Discovery of novel P3 sulfonamide-capped inhibitors of HCV NS3 protease. Inhibitors with improved cellular potencies

  摘要：

  Hepatitis C Virus (HCV) infection is the major cause of chronic liver disease, leading to cirrhosis and hepatocellular carcinoma, which affects more than 200 million people worldwide. Currently the only therapeutic regimens are subcutaneous interferon-alpha or PEG-interferon alone or in combination with oral ribavirin. Although combination therapy is reasonably successful with the majority of genotypes, its efficacy against the predominant genotype (genotype 1) is moderate at best, with only similar to 50% of the patients showing sustained virological response. We recently disclosed the discovery of Boceprevir, SCH 503034 (1), which is a novel, potent, selective, orally bioavailable NS3 protease inhibitor that has been shown to be efficacious in humans and is currently undergoing clinical trials. As second generation compounds, we have further explored various novel structures with the aim of improving enzyme and cellular binding activities of 1. Herein, we disclose our efforts toward the identification of a novel P-3 sulfonamide-capped inhibitor that demonstrated improved binding and cellular activity compared to 1. X-ray structure of one of these inhibitors bound to the enzyme revealed a hydrogen bond of the P-3 sulfonamide group to Cys159 which resulted in improved binding and cellular potency. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2009.05.012

文献信息

• Harnessing Alkyl Amines as Electrophiles for Nickel-Catalyzed Cross Couplings via C–N Bond Activation
  作者：Corey H. Basch、Jennie Liao、Jianyu Xu、Jacob J. Piane、Mary P. Watson

  DOI：10.1021/jacs.7b02389

  日期：2017.4.19

  strategy to harness alkyl amines as alkylating agents via C-N bond activation. This Suzuki-Miyaura cross coupling of alkylpyridinium salts, readily formed from primary amines, is the first example of a metal-catalyzed cross coupling via C-N bond activation of an amine with an unactivated alkyl group. This reaction enjoys broad scope and functional group tolerance. Primary and secondary alkyl groups can be

  我们开发了一种通过 CN 键活化利用烷基胺作为烷化剂的策略。这种烷基吡啶盐的 Suzuki-Miyaura 交叉偶联很容易由伯胺形成，是金属催化交叉偶联的第一个例子，通过 CN 键活化胺与未活化的烷基。该反应具有广泛的范围和官能团耐受性。可以安装伯和仲烷基。初步研究表明 NiI/NiIII 催化循环。
• [EN] ASPARTYL PROTEASE INHIBITORS<br/>[FR] INHIBITEURS DE L'ASPARTYLE PROTÉASE
  申请人：MEDIVIR AB

  公开号：WO2009053277A1

  公开（公告）日：2009-04-30

  The invention provides compounds of the formula (I) wherein A is selected from the partial structures A1, A2 and A3; Ry and Ry' are both hydrogen, or Ry and Ry' together with the nitrogen atom to which they are attached form a cyclic amine such as morpholine, piperidine, piperazine or pyrrolidine; L is NHNH, CH2NH, O or S; Y is NH, NHNH, NHC(=O), S(=O)2NH, NHS(=O)2, CH2, CH2NH, O, S or S(=0)p; Q is aryl or heterocyclyl; Z is O, S, NRa or S(=0)p; m is O, 1 or 2; n is O, 1, 2 or 3; p is independently 1 or 2; q is 0 or 1; Ra is H or C1-C4alkyl; R1 is hydrogen, C1-C6alkyl, C3-C7cycloalkylC0-C3alkyl, arylC0-C3alkyl or heterocyclylC0-C3alkyl, R4'' is H or C1-C6alkyl; or R4' and R4'' together with the carbon atom to which they are attached define a C3-C6cycloalkyl; W is H, C1-C6alkyl, C3-C7ycycloalkyl, aryl or heterocyclyl; or a pharmaceutically acceptable salt, hydrate or N-oxide thereof. The compounds of the invention are inhibitors of aspartyl proteases such as renin and are among other things useful for the treatment of conditions associated with activities of the RAS, such as hypertension, heart failure and renal insufficiency.

  该发明提供了以下式（I）的化合物，其中A从部分结构A1、A2和A3中选择；Ry和Ry'都是氢，或者Ry和Ry'与它们连接的氮原子一起形成环状胺，如吗啉、哌啶、哌嗪或吡咯烷；L为NHNH、CH2NH、O或S；Y为NH、NHNH、NHC(=O)、S(=O)2NH、NHS(=O)2、CH2、CH2NH、O、S或S(=0)p；Q为芳基或杂环烷基；Z为O、S、NRa或S(=0)p；m为O、1或2；n为O、1、2或3；p独立地为1或2；q为0或1；Ra为H或C1-C4烷基；R1为氢、C1-C6烷基、C3-C7环烷基C0-C3烷基、芳基C0-C3烷基或杂环烷基C0-C3烷基，R4''为H或C1-C6烷基；或R4'和R4''与它们连接的碳原子一起定义为C3-C6环烷基；W为H、C1-C6烷基、C3-C7环烷基、芳基或杂环烷基；或其药学上可接受的盐、水合物或N-氧化物。该发明的化合物是天冬氨酸蛋白酶的抑制剂，如肾素，用于治疗与RAS活动相关的疾病，如高血压、心力衰竭和肾功能不全等。
• Isoselenocyanates derived from Boc/Z-amino acids: synthesis, isolation, characterization, and application to the efficient synthesis of unsymmetrical selenoureas and selenoureidopeptidomimetics
  作者：Gundala Chennakrishnareddy、Govindappa Nagendra、Hosahalli P. Hemantha、Ushati Das、Tayur N. Guru Row、Vommina V. Sureshbabu

  DOI：10.1016/j.tet.2010.06.082

  日期：2010.8

  Isoselenocyanates derived from Boc/Z-amino acids are prepared by the reaction of the corresponding isonitriles with selenium powder in presence of triethylamine at reflux. The utility of these new classes of isoselenocyanates in the preparation of selenoureidodipeptidomimetics possessing both amino as well as carboxy termini has been accomplished. The H-1 NMR analysis confirmed that the protocol involving the conversion of isonitriles to isoselenocyanates and their use as coupling agents in assembling selenour-eido derivatives is free from racemization. (C) 2010 Elsevier Ltd. All rights reserved.
• INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE
  申请人：MERCK & CO., INC.

  公开号：EP0833633A1

  公开（公告）日：1998-04-08
• EP0833633A4
  申请人：——

  公开号：EP0833633A4

  公开（公告）日：1999-03-24